

## PRIOR AUTHORIZATION REQUEST

## **Orenitram**

#### **Patient Information:**

Name:	
Member ID:	
Address:	
City, State, Zip:	
Date of Birth:	

#### **Prescriber Information:**

Name:	
NPI:	
Phone Number:	
Fax Number	
Address:	
City, State, Zip:	

#### **Requested Medication**

Rx Name:	
Rx Strength	
Rx Quantity:	
Rx Frequency:	
Rx Route of	
Administration:	
Diagnosis and ICD Code:	

Your patient's prescription benefit requires that we review certain requests for coverage with the prescriber. You have prescribed a medication for your patient that requires Prior Authorization before benefit coverage or coverage of additional quantities can be provided. Please complete the following questions then fax this form to the toll-free number listed below. Upon receipt of the completed form, prescription benefit coverage will be determined based on the plan's rules.

# **SECTION A:** Please note that supporting clinical documentation is required for **ALL** PA requests. Pharmacy prior authorization reviews can be subject to trial with additional medications that are not listed within the criteria. The policies are subject to change based on COMAR requirements. MDH transmittals and updates to treatment guidelines.

If you have any		Varaian 07 2025	
3	Is the medication being prescribed by, or in consultation with, a cardiologist or a	Yes	No
2	Does the patient have WHO Group 1 PAH? [If no, no further questions.]	Yes	No
	[] Other (If checked, no further questions)		
1	What is the diagnosis or indication? [] Pulmonary arterial hypertension (PAH) World Health Organization (WHO) Group 1 (If checked, go to 2)		

questions, call: 1-888-258-8250

Version 07.2025

# **PRIOR AUTHORIZATION REQUEST**

	pulmonologist? [If no, no further questions.]		
4	Is the patient currently receiving the requested medication? [If yes, skip to question 7.]	Yes	No
5	Is documentation provided to confirm that the patient has had a right heart catheterization? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.]	Yes	No
6	Did the results of the right heart catheterization confirm the diagnosis of WHO Group 1 PAH? [If yes, skip to question 9.] [If no, no further questions.]	Yes	No
7	Has the patient had a right heart catheterization? [If no, no further questions.]	Yes	No
8	Did the results of the right heart catheterization confirm the diagnosis of WHO Group 1 PAH? [No further questions.]	Yes	No
9	Has the patient tried TWO oral therapies for PAH (or is currently receiving them) from two of the three following different categories (either alone or in combination) each for greater than or equal to 60 days: A) One phosphodiesterase type 5 (PDE5) inhibitor, B) One endothelin receptor antagonist (ERA), or C) Adempas (riociguat tablets)? [NOTE: Examples of PDE5 inhibitors include Revatio (sildenafil tablets and suspension), Adcirca (tadalafil tablets), and Alyq (tadalafil tablets), and examples of ERAs include Tracleer (bosentan tablets), Letairis (ambrisentan tablets [generic]), and Opsumit (macitentan tablets).] [If yes, no further questions.]	Yes	No
10	Is the patient receiving, or has received in the past, one prostacyclin therapy for PAH or a prostacyclin receptor agonist (for example, Uptravi) for PAH? [NOTE: Examples of prostacyclin therapies for PAH include Tyvaso (treprostinil inhalation solution), Ventavis (iloprost inhalation solution), Remodulin (treprostinil injection), and epoprostenol injection (Flolan, Veletri).]	Yes	No

### Please document the diagnoses, symptoms, and/or any other information important to this review:



# **PRIOR AUTHORIZATION REQUEST**

## SECTION B: Physician Signature

PHYSICIAN SIGNATURE

DATE

# **FAX COMPLETED FORM TO: 1-833-896-0656**

**Disclaimer:** An authorization is not a guarantee of payment. Member must be eligible at the time services are rendered. Services must be a covered Health Plan Benefit and medically necessary with prior authorization as per Plan policy and procedures.

**Confidentiality:** The information contained in this transmission is confidential and may be protected under the Health Insurance Portability and Accountability Act of 1996. If you are not the intended recipient any use, distribution, or copying is strictly prohibited. If you have received this facsimile in error, please notify us immediately and destroy this document.